Dongwha Pharm.Co.,Ltd (000020.KS)
KRW 6270.0
(-0.16%)
KRW 6270.0
(-0.16%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 25.3 Billion KRW | -37.24% |
| 2022 | 29.91 Billion KRW | 32.98% |
| 2021 | 22.49 Billion KRW | -2.84% |
| 2020 | 23.15 Billion KRW | 35.44% |
| 2019 | 17.09 Billion KRW | 52.28% |
| 2018 | 11.22 Billion KRW | 2.17% |
| 2017 | 10.98 Billion KRW | -2.42% |
| 2016 | 11.25 Billion KRW | 133.94% |
| 2015 | 4.81 Billion KRW | -38.25% |
| 2014 | 7.79 Billion KRW | 277.95% |
| 2013 | 2.06 Billion KRW | -79.38% |
| 2012 | 10 Billion KRW | -60.96% |
| 2011 | 25.62 Billion KRW | 148.34% |
| 2010 | 10.31 Billion KRW | -16.72% |
| 2009 | 12.38 Billion KRW | -69.0% |
| 2008 | 39.96 Billion KRW | 19.14% |
| 2007 | 33.54 Billion KRW | 136.71% |
| 2006 | 14.17 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 4.59 Billion KRW | -28.86% |
| 2024 Q1 | 6.48 Billion KRW | 514.05% |
| 2023 Q2 | 5.46 Billion KRW | -55.14% |
| 2023 Q1 | 12.18 Billion KRW | 678.11% |
| 2023 Q4 | -1.56 Billion KRW | -158.12% |
| 2023 Q3 | 2.69 Billion KRW | -50.69% |
| 2023 FY | 18.77 Billion KRW | -37.24% |
| 2022 Q1 | 9.05 Billion KRW | 39.0% |
| 2022 Q3 | 7.41 Billion KRW | -26.49% |
| 2022 Q4 | 1.56 Billion KRW | -78.9% |
| 2022 FY | 29.91 Billion KRW | 32.98% |
| 2022 Q2 | 10.09 Billion KRW | 11.49% |
| 2021 Q1 | 5.11 Billion KRW | -27.14% |
| 2021 FY | 22.49 Billion KRW | -2.84% |
| 2021 Q2 | 7.19 Billion KRW | 40.64% |
| 2021 Q3 | 3.66 Billion KRW | -49.1% |
| 2021 Q4 | 6.51 Billion KRW | 77.72% |
| 2020 Q4 | 7.02 Billion KRW | -2.37% |
| 2020 Q3 | 7.19 Billion KRW | 15.64% |
| 2020 Q2 | 6.22 Billion KRW | 129.91% |
| 2020 FY | 23.15 Billion KRW | 35.44% |
| 2020 Q1 | 2.7 Billion KRW | -65.33% |
| 2019 Q4 | 7.8 Billion KRW | 1037.97% |
| 2019 Q2 | -865.07 Million KRW | -137.79% |
| 2019 Q1 | 2.28 Billion KRW | 0.0% |
| 2019 FY | 17.09 Billion KRW | 52.28% |
| 2019 Q3 | 686.08 Million KRW | 179.31% |
| 2018 Q4 | - KRW | -100.0% |
| 2018 FY | 11.22 Billion KRW | 2.17% |
| 2018 Q2 | 836.96 Million KRW | -84.54% |
| 2018 Q1 | 5.41 Billion KRW | 3879.46% |
| 2018 Q3 | 1.55 Billion KRW | 86.15% |
| 2017 Q3 | 2.18 Billion KRW | -49.11% |
| 2017 FY | 10.98 Billion KRW | -2.42% |
| 2017 Q4 | -143.24 Million KRW | -106.56% |
| 2017 Q1 | 4.65 Billion KRW | 820.69% |
| 2017 Q2 | 4.29 Billion KRW | -7.82% |
| 2016 FY | 11.25 Billion KRW | 133.94% |
| 2016 Q1 | 6.56 Billion KRW | 180.27% |
| 2016 Q2 | 2.1 Billion KRW | -67.86% |
| 2016 Q3 | 2.08 Billion KRW | -1.33% |
| 2016 Q4 | 505.65 Million KRW | -75.7% |
| 2015 Q1 | 2.2 Billion KRW | 21.46% |
| 2015 Q4 | 2.34 Billion KRW | 321.41% |
| 2015 Q3 | -1.05 Billion KRW | -180.01% |
| 2015 Q2 | 1.32 Billion KRW | -40.1% |
| 2015 FY | 4.81 Billion KRW | -38.25% |
| 2014 Q2 | 2.22 Billion KRW | -20.53% |
| 2014 Q1 | 2.79 Billion KRW | 249.96% |
| 2014 FY | 7.79 Billion KRW | 277.95% |
| 2014 Q4 | 1.81 Billion KRW | 89.98% |
| 2014 Q3 | 956.36 Million KRW | -56.98% |
| 2013 Q3 | -2.34 Billion KRW | -267.16% |
| 2013 FY | 2.06 Billion KRW | -79.38% |
| 2013 Q1 | 4.87 Billion KRW | 528.69% |
| 2013 Q2 | 1.4 Billion KRW | -71.18% |
| 2013 Q4 | -1.86 Billion KRW | 20.49% |
| 2012 Q4 | 774.69 Million KRW | -78.35% |
| 2012 Q1 | 2.49 Billion KRW | 62.89% |
| 2012 Q2 | 3.15 Billion KRW | 26.69% |
| 2012 FY | 10 Billion KRW | -60.96% |
| 2012 Q3 | 3.57 Billion KRW | 13.29% |
| 2011 FY | 25.62 Billion KRW | 148.34% |
| 2011 Q2 | 8.69 Billion KRW | -23.26% |
| 2011 Q4 | 1.53 Billion KRW | -62.36% |
| 2011 Q1 | 11.33 Billion KRW | 95.1% |
| 2011 Q3 | 4.06 Billion KRW | -53.24% |
| 2010 Q3 | 1.18 Billion KRW | 280.34% |
| 2010 Q4 | 5.8 Billion KRW | 390.21% |
| 2010 Q1 | 2.93 Billion KRW | 0.0% |
| 2010 FY | 10.31 Billion KRW | -16.72% |
| 2010 Q2 | 311.48 Million KRW | -89.39% |
| 2009 Q2 | 6.05 Billion KRW | -60.32% |
| 2009 Q1 | 15.24 Billion KRW | 83.8% |
| 2009 FY | 12.38 Billion KRW | -69.0% |
| 2009 Q3 | 4.06 Billion KRW | -32.85% |
| 2008 FY | 39.96 Billion KRW | 19.14% |
| 2008 Q3 | 6.42 Billion KRW | -35.73% |
| 2008 Q4 | 8.29 Billion KRW | 29.13% |
| 2008 Q2 | 9.99 Billion KRW | -18.07% |
| 2008 Q1 | 12.2 Billion KRW | 66.97% |
| 2007 Q4 | 7.3 Billion KRW | -7.64% |
| 2007 FY | 33.54 Billion KRW | 136.71% |
| 2007 Q2 | 6.12 Billion KRW | 0.0% |
| 2007 Q3 | 7.91 Billion KRW | 29.12% |
| 2006 FY | 14.17 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuhan Corporation | 74.56 Billion KRW | 66.066% |
| Yuhan Corporation | 74.56 Billion KRW | 66.066% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -6840.878% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -6840.878% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -6840.878% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 131.802% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -291.006% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 67.09% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 74.775% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 74.775% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 74.775% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 240.236% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 23.667% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -4142.447% |
| HANDOK Inc. | 12.57 Billion KRW | -101.148% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -20.946% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 1372.009% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 167.478% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 136.171% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 426.224% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 21.502% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -711.642% |
| Boryung Corporation | 68.26 Billion KRW | 62.937% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -265.271% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -23.519% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -76.316% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -76.316% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 41.151% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 48.117% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -727.931% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 22.208% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -2525.336% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 153.388% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 153.388% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 53.954% |
| CKD Bio Corp. | -20.15 Billion KRW | 225.553% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 81.034% |
| JW Holdings Corporation | 143.66 Billion KRW | 82.388% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -527.278% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 88.749% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -126.347% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 89.74% |
| JW Lifescience Corporation | 32.09 Billion KRW | 21.156% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 147.367% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -189.783% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 6.398% |